Skip to main content

CAR T-Cell Clinical Trials

 
 

The Bone Marrow Transplantation & Cellular Therapy Department conducts CAR T-cell clinical trials for children and young adults with relapsed or refractive leukemia. These studies use chimeric antigen receptor (CAR) products developed and produced at the Children’s GMP, LLC, which is located on the St. Jude campus.

St. Jude Clinical Trials

 
 

3CAR: B7-H3-specific CAR T-cell Therapy for Children and Young Adults with Solid Tumors

Diseases Treated:

Solid Tumors

Eligibility:

Inclusion criteria include:

  • 21 years old or younger
  • Relapsed or refractory B7-H3-positive solid tumor
View Trial

CATCHAML: CAR T-Cell Therapy for Acute Myelogenous Leukemia (AML)

Diseases Treated:

Acute Myelogenous Leukemia

Eligibility:

  • 21 years old or younger
  • Relapsed/refractory CD123+ AML, B-ALL, T-ALL or blastic plasmacytoid dendritic cell neoplasm
  • Has a suitable bone marrow transplant donor for allogeneic bone marrow transplant
View Trial

Loc3CAR: CAR T-Cell Therapy for Pediatric CNS Tumors

Diseases Treated:

Brain tumors
DIPG

Eligibility:

  • Up to 21 years old
  • Either B7-H3–positive relapsed or refractory non-brainstem primary CNS tumor or brainstem high-grade neoplasm
View Trial

MEMCAR19: Allogeneic CAR T-Cell Therapy for Relapsed/Refractory CD19-Positive Leukemia

Diseases Treated:

Acute lymphoblastic leukemia

Eligibility:

Donor eligibility includes:

  • At least 18 years old
  • At least single haplotype matched family member
  • HIV negative
  • Not pregnant or breastfeeding

Recipient eligibility includes:

  • 21 years old or younger*
  • Diagnosed with relapsed and/or refractory CD19-positive leukemia
  • Cohort A only – Relapsed and/or refractory CD19-positive leukemia AND previously received a hematopoietic cell transplant from the selected CAR-T donor
  • Cohort B only: Can not receive autologous CD19-CAR T-cell therapy (per study)
  • Detectable medullary leukemia

* Initial 3 participants must be at least 16 years old.

View Trial

SJCAR19: CAR T-Cell Therapy for Children and Young Adults with Acute Lymphoblastic Leukemia

Diseases Treated:

Acute lymphoblastic leukemia

Eligibility:

 

 

View Trial
Close